## 1

### US China Relations

#### Despite growing rivalry, US-China economic interdependence strong now. Exchange of tech know-how, collaboration science research, and massive US-China STEM pipeline improving relations – but it can easily collapse.

Hass 8/12 [Ryan Hass (Senior Fellow - Foreign Policy, Center for East Asia Policy Studies, John L. Thornton China Center The Michael H. Armacost Chair Chen-Fu and Cecilia Yen Koo Chair in Taiwan Studies Nonresident Fellow, Paul Tsai China Center, Yale Law School), 8-12-2021, "The “new normal” in US-China relations: Hardening competition and deep interdependence," Brookings, <https://www.brookings.edu/blog/order-from-chaos/2021/08/12/the-new-normal-in-us-china-relations-hardening-competition-and-deep-interdependence/> // belle]

The intensification of U.S.-China competition has captured significant attention in recent years. American attitudes toward China have become more negative during this period, as anger has built over disruptions resulting from the COVID-19 pandemic, Beijing’s trampling of Hong Kong’s autonomy, human rights violations in Xinjiang, and job losses to China.

Amidst this focus on great power competition, two broader trends in the U.S.-China relationship have commanded relatively less attention. The first has been the widening gap in America’s and China’s overall national power relative to every other country in the world. The second has been the continuing thick interdependence between the United States and China, even amidst their growing rivalry. Even on economic issues, where rhetoric and actions around decoupling command the most attention, trade and investment data continue to point stubbornly in the direction of deep interdependence. These trends will impact how competition is conducted between the U.S. and China in the coming years.

SEPARATING FROM THE PACK

As America’s unipolarity in the international system has waned, there has been renewed focus on the role of major powers in the international system, including the European Union, Russia, India, and Japan. Each of these powers has a major population and substantial economic weight or military heft, but as my Brookings colleague Bruce Jones has observed, none have all. Only the United States and China possess all these attributes.

The U.S. and China are likely to continue amassing disproportionate weight in the international system going forward. Their growing role in the global economy is fueled largely by both countries’ technology sectors. These two countries have unique traits. These include world-class research expertise, deep capital pools, data abundance, and highly competitive innovation ecosystems. Both are benefitting disproportionately from a clustering effect around technology hubs. For example, of the roughly 4,500 artificial intelligence-involved companies in the world, about half operate in the U.S. and one-third operate in China. According to a widely cited study by PricewaterhouseCoopers, the U.S. and China are set to capture 70% of the $15.7 trillion windfall that AI is expected to add to the global economy by 2030.

The United States and China have been reinvesting their economic gains to varying degrees into research and development for new and emerging technologies that will continue to propel them forward. While it is not foregone that the U.S. and China will remain at the frontier of innovation indefinitely, it also is not clear which other countries might displace them or on what timeline. Overall, China’s economy likely will cool in the coming years relative to its blistering pace of growth in recent decades, but it is not likely to collapse.

DEEP INTERDEPENDENCE

At the same time, bilateral competition between the United States and China also is intensifying. Even so, rising bilateral friction has not – at least not yet – undone the deep interdependencies that have built up between the two powers over decades.

In the economic realm, trade and investment ties remain significant, even as both countries continue to take steps to limit vulnerabilities from the other. For example, Chinese regulators have been asserting greater control over when and where Chinese companies raise capital; Beijing’s recent probe of ride-hailing app Didi Chuxing provides but the latest example. China’s top leaders have been emphasizing the need for greater technology “self-sufficiency” and have been pouring billions of dollars of state capital into this drive. Meanwhile, U.S. officials have been seeking to limit American investments from going to Chinese companies linked to the military or surveillance sectors. The Security and Exchange Commission’s scrutiny of initial public offerings for Chinese companies and its focus on ensuring Chinese companies meet American accounting standards could result in some currently listed Chinese companies being removed from U.S. exchanges. Both countries have sought to disentangle supply chains around sensitive technologies with national security, and in the American case, human rights dimensions. U.S. officials have sought to raise awareness of the risks for American firms of doing business in Hong Kong and Xinjiang.

Even so, U.S.-China trade and investment ties remain robust. In 2020, China was America’s largest goods trading partner, third largest export market, and largest source of imports. Exports to China supported an estimated 1.2 million jobs in the United States in 2019. Most U.S. companies operating in China report being committed to the China market for the long term.

U.S. investment firms have been increasing their positions in China, following a global trend. BlackRock, J.P. Morgan Chase, Goldman Sachs, and Morgan Stanley have all increased their exposure in China, matching similar efforts by UBS, Nomura Holdings, Credit Suisse, and AXA. The Rhodium Group estimates that U.S. investors held $1.1 trillion in equities issued by Chinese companies, and that there was as much as $3.3 trillion in U.S.-China two-way equity and bond holdings at the end of 2020.

One leg of the U.S.-China economic relationship that has atrophied in recent years has been China’s flow of investment into the United States. This has largely been a product of tightened capital controls in China, growing Chinese government scrutiny of its companies’ offshore investments, and enhanced U.S. screening of Chinese investments for national security concerns.

Another area of U.S.-China interdependence has been knowledge production. As U.S.-China technology expert Matt Sheehan has observed, “With the rise of Chinese talent and capital, the exchange of technological know-how between the United States and China now takes place among private businesses and between individuals.” Leading technology companies in both countries have been building research centers in the other. Alibaba, Baidu, and Tencent have all opened research centers in the United States, just as Apple, Microsoft, Tesla, and other major American technology companies rely upon engineering talent in China.

In science collaboration, The Nature Index ranks the joint research between the two countries as the world’s most academically fertile. U.S.-China scientific collaboration grew by more than 10% each year on average between 2015 and 2019. Even following the global spread of COVID-19, American and Chinese experts collaborated more during the past year than over the previous five years combined. This has led to over 100 co-authored articles in leading scientific journals and frequent joint appearances in science-focused workshops and webinars.

China also is the largest source of international students in the United States. In the 2019-20 year, there were over 370,000 Chinese students in the U.S., representing 34% of international students in colleges and universities. Up until now, many of the top Chinese students have stayed in the United States following graduation and contributed to America’s scientific, technological, and economic development. It remains to be seen whether this trend will continue.

COMPETITIVE INTERDEPENDENCE

The scale of American and Chinese interests implicated will likely induce sobriety over time in Washington and Beijing as to how the relationship is managed. The U.S. policy focus for the foreseeable future is not likely to be seeking to “defeat” China or compel the collapse of the Chinese Communist Party. Rather, the focus will be on taking steps at home and with partners abroad to strengthen America’s long-term competitiveness vis-à-vis China. At the same time, American leaders will continue to push their Chinese counterparts to improve the treatment of their citizens. Such efforts are definitional to America’s self-identity as a champion of values.

The dense webs formed by trade, financial, scientific, and academic links between the United States and China will make it difficult for one side to inflict harm on the other without hurting itself in the process. As Joe Nye has written, “America can decouple security risks like Huawei from its 5G telecommunications network, but trying to curtail all trade with China would be too costly. And even if breaking apart economic interdependence were possible, we cannot decouple the ecological interdependence that obeys the laws of biology and physics, not politics.”

President Joe Biden likely will use the challenges posed by China as a spur for his domestic resilience agenda. He is not an ideologue, though, and is unlikely to limit his own flexibility by painting the world with permanent black and white dividing lines. The Biden team knows it will be harder to realize progress on serious global challenges like climate change, pandemics, and inclusive global economic recovery without pragmatic dealings with non-democratic states.

Major near-term improvements to the U.S.-China relationship are unlikely, barring an unexpected moderation in Beijing’s behavior. At the same time, the relationship is also unlikely to tip into outright hostility, barring an unforeseen dramatic event, such as a Chinese act of aggression against an American security partner.

U.S.-China relations are going to be hard-nosed and tense. Neither side is likely to offer concessions in service of smoother relations. At the same time, the balance of interests on both sides likely will control hostile impulses, placing the relationship in a state of hardening competition that coexists alongside a mutual awareness that both sides will be impacted — for good or ill — by their capacity to address common challenges.

#### Plan hurts US-China relations – means China goes back on it’s promise to regulate IP violations and draws in U.S. crackdown.

Shape 2/19 [Steven M. Shape; registered patent attorney and electrical engineer who has represented preeminent technology companies in complex, high-stakes Intellectual Property litigation; 2-19-2021, "IP Law Looms Large Over U.S.-China Relations," No Publication, [https://www.mondaq.com/trademark/1038030/ip-law-looms-large-over-us-china-relations //](https://www.mondaq.com/trademark/1038030/ip-law-looms-large-over-us-china-relations%20//) belle]

The U.S. and China were indisputably the two largest parties in the global trade war that consumed much of the last several years. Particularly between early 2018 and late 2019, it seemed as if one could hardly go a week, if that, without hearing something about tariffs, exports, imports, steel, soybeans, then-President Donald Trump, President Xi Jinping and the like. Accusations regarding violations of Intellectual Property law were among the biggest flashpoints, and ultimately, China announced new regulations concerning IP protection in November 2019 as a conciliatory move. Nearly 14 months later, newly inaugurated President Joe Biden has yet to fully clarify his administration's stance toward China. However, it is inevitable that IP rights and their preservation will factor into negotiations between the two economic giants. A look back at the proposed reforms (and their effects) Reports from CNN at the time claimed that China's prospective IP law reforms focused on making the penalties for IP infringement more strict. It would also put the government's increasingly modernized tech infrastructure to use in the discovery and prosecution of such crimes. Beyond that, the proposal carried few specifics. Although it is unclear whether Beijing's gambit worked as the deciding factor for Washington, it certainly did not fail. The two nations agreed in principle on "Phase One" of a new trade agreement December 12, 2019, per The Washington Post, and formalized the deal about a month later. The U.S. pledged not to impose further tariffs and roll back existing import taxes in return for China's IP reforms and agreement to buy American goods. In the 14 months that followed, so much changed. COVID-19's devastating impact on human life and the global economy made it difficult to gauge the positive effects of the tariff relief or IP reform. A report by the South China Morning Post found that China did not meet its import goal for 2020, with some analysts concluding the Phase One target was unrealistic. On the IP front, a Hong Kong news provider noted that Beijing had drafted some specific guidance to protect pharmaceutical patents, trade secrets and copyrights, but it was unclear how well they were being implemented. Additionally, a January 2021 report by the U.S. Patent and Trademark Office (USPTO) found that Chinese policies which offered subsidies for certain trademark and patent applications helped motivate a glut of fraudulent and bad-faith filings in the last few years. The bigger picture of China's IP law A casual observer or someone just learning of this issue might assume that until recently, China had little or no IP laws on the books. Of course, that is not true. However, there are many factors at play complicating the matter of Chinese IP protection policies. As noted in Harvard Business Review, China is quite strict in certain aspects of IP protection: Beijing allows (and encourages) all businesses to impose non-compete agreements to help protect trade secrets and other IP assets. In addition, according to the National Law Review, two new measures were passed in 2020 specifically to combat bad-faith trademark applications, in addition to the other new guidelines being imposed by the China National Intellectual Property Administration (CNIPA) in accordance with the Phase One agreement. All that said, it would be inaccurate to describe Chinese IP law as thoroughly protective for either domestic or foreign innovators. Along with the aforementioned trademark and patent subsidies, considerable controversy stems from "forced technology transfer" policies. According to the University of Oxford's Business Law Blog, foreign companies looking to do business in China must turn over their technology to local firms or be denied the right to operate within China. This effectively means turning over the blueprints (literal or otherwise) to such technology - which is all but equivalent to surrendering the IP. It creates considerable opportunities for infringement, fraud and corruption. Also, in disputes with foreign firms, some local IP courts still markedly favor domestic organizations. Chinese government representatives often resent such accusations of bias or corruption. In their view, the deals represent friendly agreements between businesses, and courts' decisions are not politically motivated. While Oxford noted that FTT guidelines are not as pervasive now as they were a few years ago, they have yet to disappear altogether. The Biden approach: Not dissimilar, but multilateral If the new U.S. Secretary of the Treasury, Janet Yellen, is to be believed, the Biden administration will not tolerate any signs of lapses in China's IP protections. "We need to take on China's abusive, unfair and illegal practices," Yellen said to the Senate Finance Committee at her confirmation hearings. As reported by Bloomberg, she added, "[China has] been stealing intellectual property and engaging practices that give it an unfair technological advantage, including forced technology transfers. And these . are practices that we're prepared to use the full array of tools to address." Biden had expressed similar sentiments during a December interview with The New York Times. However, he also said that they would work with ally nations to "develop a coherent strategy" for addressing cases of IP infringement and other issues - a stance Yellen echoed before the Senate - instead of taking China on in a unilateral and bellicose manner. This more nuanced approach could yield greater cooperation from Beijing and help repair U.S.-China trade relations, but we will likely not know one way or the other for some time. As we saw with the trade war, conflicts between the U.S. and China can quickly escalate and have ripple effects throughout the world. It would thus be wise for all organizations doing business in China to keep themselves abreast of the country's evolving IP regulations and work with a reliable IP services provider to help establish strong protection for their intangible assets.

#### Maintaining US-China relations key to confidence building, dialogue measures, and address mutual anxieties about nukes -- that prevents nuke war.

CSIS ’13 [CSIS (CSIS is a nonprofit organization headquartered in Washington, D.C. The Center’s 220 full- time staff and large network of affiliated scholars conduct research and analysis and develop policy initiatives that look into the future and anticipate change), March 2013, " Nuclear Weapons and U.S.-China Relations a way forward," Center for Strategic and International Studies, <https://csis-website-prod.s3.amazonaws.com/s3fs-public/legacy_files/files/publication/130307_Colby_USChinaNuclear_Web.pdf> // belle]

The United States has long seen China as a central factor in its strategy in Asia. Since the 1970s, U.S. policy has sought to encourage China’s economic reforms and development and to integrate China into the existing international political and economic order. While hopeful that China will develop into a constructive stakeholder, the United States and much of the Asia-Pacific region share continuing concerns about some aspects of China’s behavior that, it is feared, could undermine regional stability and U.S. interests in the Asia-Pacific.

Unfortunately, significant sources of tension and disagreement between the United States and its allies, on the one hand, and China, on the other, remain. These sources of discord could, in the worst case, lead to conflict. Needless to say, a large-scale conventional war between the United States and China would be incredibly dangerous and likely tremendously damaging. Nuclear war between the two would be devastating for all involved. Even though a conventional war between the two nations currently seems unlikely and nuclear war even more so, the possibility that war could break out, posing dramatic dangers and damage, clearly indicates that active steps should be taken to avoid conflict and successfully manage U.S.-China nuclear dynamics.

Significance and Objectives of U.S.-China Nuclear Relations

Maintaining stability in U.S.-China nuclear relations will be critical to the interests of the United States and those of its allies and security partners in the coming years. The Working Group judges that the nuclear dynamics between the United States and China are relatively stable at this time, primarily because both sides have or will soon have a nuclear deterrent of the size and scope they determine they need, and China appears committed to a relatively restrained posture oriented around a “lean and effective” nuclear force and its no-first-use policy. Yet the Working Group is concerned that the changing conventional military balance of power in the region, the current sources of tension and possible conflict, and the expansion of the quality and quantity of China’s nuclear arsenal raise serious questions about the future stability of U.S-China nuclear relations. The recommendations contained in this report are therefore focused on enhancing nuclear stabil- ity between the United States and China, primarily by advocating a series of both bilateral and unilat- eral policy and posture adjustments that would enhance crisis stability and arms race stability, while also laying the groundwork for future bilateral and multilateral nuclear engagement.

Because the current nuclear dynamics are broadly stabilizing and should be sustained, the Working Group recommends that U.S.-China nuclear relations be oriented toward sustaining these dynamics and avoiding decisions by either side that could erode stability. We therefore recommend a robust but realistically tailored program of engagement and dialogue on nuclear issues that reinforce China’s nuclear restraint and advance U.S. interests in stability, dialogue, transparency, and prog- ress toward arms control. The Working Group recognizes, however, the limited success attempts at dialogue and cooperation have thus far yielded. The Group’s recommendations are therefore de- signed to be ambitious but realistic, and are structured in such a way that, in the event that Beijing is unwilling to engage in earnest along the lines the Group advocates, the United States would be left with a powerful strategic capability and in the strong political position of having proffered a serious, fair-minded path forward in bilateral nuclear weapons relations that China had rebuffed.

The Working Group also recommends that the United States adopt a policy of accepting China’s possession of an assured second-strike nuclear capability, and thus avoid attempting to acquire the capability to negate China’s nuclear retaliatory capabilities. This judgment relies on the fundamental determination that the United States cannot realistically hope to deny China’s second-strike capability, that a failed attempt to deny it would be costly and counterproductive, and that Beijing’s possession of a reliable retaliatory capability promotes stability rather than detracts from it. In addition, this approach could reinforce China’s nuclear restraint. The Working Group is, however, divided on whether the United States should publicly and formally announce this acceptance.

The Working Group believes that some of the concepts associated with the idea of “strategic stability” provide an appropriate framework for U.S.-China engagement on nuclear weapons is- sues, although the specific meaning of the term is the subject of a long-running debate that has never been definitively settled. In order to gain the benefits of strategic stability, the Working Group believes that nuclear relations between the United States and China should emphasize two complementary approaches: crisis stability and arms race stability.

Stability can emerge between the United States and China if each fields forces that are capable of surviving a first strike and if each is able to credibly demonstrate to the other side that its cur- rent and future capabilities are not capable of denying the other side a viable strategic deterrent. As a result, fear of preemption and the need to launch weapons early become irrelevant, either as irri- tants in crisis or as dangers in conflict. In this way, the benefits of deterrence can be retained, while minimizing the chances of nuclear escalation and avoiding a competition in the development of offensive and defensive strategic arms that would intensify uncertainties for both sides.

Both sides could derive value from cooperation on nuclear weapons issues grounded in the stability concept. The United States worries about the composition of China’s nuclear force, China’s views on escalation and plans for nuclear use, and the future trajectory of China’s strategic posture. China, meanwhile, worries about the ability of the United States to deny it a second-strike capa- bility; the scope and sophistication of future U.S. nuclear, conventional prompt global strike, and missile defense programs; and U.S. unwillingness to acknowledge a condition of mutual vulner- ability between the two nations. A stability-grounded model could help address these anxiet- ies—on the U.S. side by providing greater insight into China’s current and future force structure and deeper insight into China’s ways of thinking about nuclear strategy, and on the Chinese side by providing similar insight into U.S. developments and a greater degree of assurance about U.S. acknowledgment of the survivability of the Chinese force. Concurrently, such an approach would have the added benefit of building confidence on both sides, thereby enhancing strategic trust more broadly. Finally, such a model could also provide a satisfactory way in which both nations could see something approximating their current force size, posture, and doctrine as satisfactory and compatible with stability.

#### US-China war causes extinction.

Wittner, PhD, 12

(Lawrence, History from Columbia, Professor Emeritus of History at SUNY Albany, <https://www.huffpost.com/entry/nuclear-war-china_b_1116556>) BW

Of course, the bottom line for those Americans convinced that nuclear weapons safeguard them from a Chinese nuclear attack might be that the U.S. nuclear arsenal is far greater than its Chinese counterpart. Today, it is estimated that the U.S. government possesses over 5,000 nuclear warheads, while the Chinese government has a total inventory of roughly 300. Moreover, only about 40 of these Chinese nuclear weapons can reach the United States. Surely the United States would “win” any nuclear war with China. But what would that “victory” entail? An attack with these Chinese nuclear weapons would immediately slaughter at least 10 million Americans in a great storm of blast and fire, while leaving many more dying horribly of sickness and radiation poisoning. The Chinese death toll in a nuclear war would be far higher. Both nations would be reduced to smoldering, radioactive wastelands. Also, radioactive debris sent aloft by the nuclear explosions would blot out the sun and bring on a “nuclear winter” around the globe — destroying agriculture, creating worldwide famine, and generating chaos and destruction. Moreover, in another decade the extent of this catastrophe would be far worse. The Chinese government is currently expanding its nuclear arsenal, and by the year 2020 it is expected to more than double its number of nuclear weapons that can hit the United States. The U.S. government, in turn, has plans to spend hundreds of billions of dollars “modernizing” its nuclear weapons and nuclear production facilities over the next decade. To avert the enormous disaster of a U.S.-China nuclear war, there are two obvious actions that can be taken. The first is to get rid of nuclear weapons, as the nuclear powers have agreed to do but thus far have resisted doing. The second, conducted while the nuclear disarmament process is occurring, is to improve U.S.-China relations. If the American and Chinese people are interested in ensuring their survival and that of the world, they should be working to encourage these policies.

## 2

### Infrastructure

#### Infrastructure is making halting progress via reconciliation – bipartisanship is key for Manchin and Republicans to not nuke it

Litvan 9/2 [Laura] “Manchin Jolts Democrats by Urging ‘Pause’ on $3.5 Trillion Bill,” Bloomberg, September 2, 2021, <https://www.bloomberg.com/news/articles/2021-09-02/manchin-tells-democrats-to-pause-on-biden-s-3-5-trillion-plan> TG

Senator Joe Manchin is demanding a “strategic pause” in action on President Joe Biden’s economic agenda, potentially imperiling the $3.5 trillion tax and spending package that Democratic leaders plan to push through Congress this fall.

The West Virginia Democrat, a linchpin vote in the evenly divided Senate, said at an event in his home state on Wednesday and in a Thursday Wall Street Journal op-ed that rising inflation and a soaring national debt necessitate a go-slow approach and a “significantly” smaller plan than the one Democratic leaders and the White House have endorsed.

“By placing a strategic pause on this budgetary proposal, by significantly reducing the size of any possible reconciliation bill to only what America can afford and needs to spend, we can and will build a better and stronger nation for all our families,” Manchin said in the op-ed.

Manchin’s resistance to the core of Biden’s economic plan caps a politically painful month for a White House that has grappled with a chaotic withdrawal from Afghanistan, a resurgent pandemic and a massive hurricane that cut a path of death and damage from Louisiana to New York.

In comments Wednesday at an event hosted by the West Virginia Chamber of Commerce, the moderate Democrat said his party should “hit the pause button.” Lawmakers, he said, have too many other pressing issues before them, including heightening national security concerns after the Taliban takeover of Afghanistan.

“Let’s sit back. Let’s see what happens. We have so much on our plate,” he said.

Manchin’s comments come as Democratic leaders and committee chairs in the Senate and House work out the specifics of the economic package, with a goal of moving it through Congress soon after lawmakers return from a recess later this month. All members of the Senate Democratic caucus would have to back the measure for it to get the 51 votes needed to pass, with Vice President Kamala Harris providing the tie-breaking vote.

A spokesman for Senate Majority Leader Chuck Schumer didn’t immediately respond to a request for comment about Manchin’s request, and White House Press Secretary Jen Psaki did not immediately provide a comment.

The chair of the Congressional Progressive Caucus, Representative Pramila Jayapal, replied “Absolutely not” on Twitter to Manchin’s idea of a pause.

The spending package also is facing obstacles in the House. Democrats can only afford three defections in that chamber if Republicans are united in opposition, and some moderate Democrats also are balking at the size of the package being drawn up.

Manchin also called on the House to pass within a few weeks a Senate-passed $550 billion bipartisan infrastructure bill. House Speaker Nancy Pelosi has promised progressives in the chamber that she will marry that legislation with the much bigger Democrat-only tax-and-spending package, although moderates have been promised an infrastructure vote by late September.

#### General bipartisanship could spark compromise but the plan’s partisan nature tanks any shot

Montanari 21 “Biden’s Undermining Of U.S. Intellectual Property Rights Is Dangerous And Will Hurt Pandemic Response,” Lorenzo Montanari [executive director of Property Rights Alliance, an advocacy policy group in charge of publishing the International Property Rights Index], May 12, 2021 <https://www.forbes.com/sites/lorenzomontanari/2021/05/12/bidens-undermining-of-us-intellectual-property-rights-is-dangerous-and-will-hurt-pandemic-response/?sh=4a74c5004890> SM

Republican Congressman Byron Donalds (R-Fla.) is working on a new piece of legislation titled "Preventing Foreign Attempts to Erode Healthcare Innovation Act” to block the White House IP waiver position and to "prevent the Biden Administration from senselessly giving away America's intellectual property to countries like China”. IP rights are enshrined in Article 1, Section 8, Clause 8 of the U.S. Constitution of 1787, “To promote the progress of science and useful arts, by securing for limited times to authors and inventors the exclusive right to their respective writings and discoveries.” As a central pillar to American history and constitutionalism for 244 years, IP converges tradition and progress to enrich the lives of citizens and society.

Waiving IP rights not only goes directly against America’s core values and threatens public health but wanes potential for bipartisan efforts. “Congress has spent decades wrangling over the contours of patent protections,” WSJ’s Kimberley A. Strassel says, “producing bipartisan legislation from the Bayh-Dole Act of 1980 and the Hatch-Waxman Act of 1984 to the Leahy-Smith Act of 2011.” All these bipartisan efforts to defend American inventors with a strong and fair IP system risk being seriously damaged with this Biden move.

#### Bill key to prevent infrastructure disaster from Grid Collapse

PPG, 3/4/2021 (MAR 4, 2021 9:00 PM, Pittsburgh Post-Gazette Editorial Board. Invest in infrastructure. March 4, 2021. <https://www.post-gazette.com/opinion/editorials/2021/03/05/Invest-in-infrastructure/stories/202102270028>, recut by JMP)

Now is the time for a reckoning, a realization: While it’s important to study the past to avoid repeating the same mistakes, the country must also look to its future and see the obvious — that America’s infrastructure as a whole needs some serious upkeep.

Democrats and Republicans alike have flirted with the idea of a sweeping infrastructure bill in recent years, and President Joe Biden’s team is working to outline such legislation. These efforts should proceed swiftly — now is the time for Congress to invest in infrastructure, not only to help prevent crises, but also to jump-start an economy mired in the coronavirus pandemic.

Despite being one of the richest countries in the world, the U.S. seems constantly to hover on the edge of disaster, with news of natural forces smashing through power grids and levies and fire prevention strategies on a yearly or monthly basis. Texas is only the most recent state to have been pushed over the edge.

The American Society of Civil Engineers just this week gave America’s infrastructure an overall grade of C-minus in its quadrennial report card. The last grade was D-plus and that report cited decades of underfunding and unheeded recommendations. C-minus is an improvement but deserves not just federal attention but actual intervention. The report notes “we are heading in the right direction, but a lot of work remains.”

There is opportunity in the recent economic and environmental devastation that grabs headlines and breaks hearts. In the aftermath of the Great Depression, the government put millions to work improving parks and building roads and bridges and airports. President Dwight Eisenhower’s interstate highway system remains the life veins of interstate travel.

A new and vigorous infrastructure package for America would fix what needs to be fixed and offer the promise of an economic boon.

The purpose of the federal government is to address the needs of American society in a way that can’t be tackled by states in a piecemeal fashion. What has happened in recent days within The Lone Star State demonstrates keenly that this is the time — actually past the time — that our federal leaders must shore up the foundations of our federation. Congress should act swiftly to lead states in reversing the entropy chewing away at America’s foundations. Until this happens, society stands on shifting sands.

#### Grid collapse causes extinction.

Greene ’19 [Sherrell R.; Nuclear Engineering M.S. degrees from the University of Tennessee, recognized subject matter expert in nuclear reactor safety, nuclear fuel cycle technologies, and advanced reactor concept development, worked at the Oak Ridge National Laboratory (ORNL) for over three decades, as Director of Research Reactor Development Programs and Director of Nuclear Technology Programs; “Enhancing Electric Grid, Critical Infrastructure, and Societal Resilience with Resilient Nuclear Power Plants (rNPPs),” Nuclear Technology 205(3), <https://ans.tandfonline.com/doi/pdf/10.1080/00295450.2018.1505357?needAccess=true> recut gord0]

There are a variety of events that could deal ~~crippling~~ blows to a nation’s Grid, Critical Infrastructure, and social fabric. The types of catastrophes under consideration here are “very bad day” scenarios that might result from severe GMDs induced by solar CMEs, HEMP attacks, cyber attacks, etc.5

As briefly discussed in Sec. III.C, the probability of a GMD of the magnitude of the 1859 Carrington Event is now believed to be on the order of 1%/year. The Earth narrowly missed (by only several days) intercepting a CME stream in July 2012 that would have created a GMD equal to or larger than the Carrington Event.41 Lloyd’s, in its 2013 report, “Solar Storm Risk to the North American Electric Grid,” 42 stated the following: “A Carrington-level, extreme geomagnetic storm is almost inevitable in the future…The total U.S. population at risk of extended power outage from a Carrington-level storm is between 20-40 million, with durations of 16 days to 1-2 years…The total economic cost for such a scenario is estimated at $0.6-2.6 trillion USD.” Analyses conducted subsequent to the Lloyd’s assessment indicated the geographical area impacted by the CME would be larger than that estimated in Lloyd’s analysis (extending farther northward along the New England coast of the United States and in the state of Minnesota),43 and that the actual consequences of such an event could actually be greater than estimated by Lloyd’s.

Based on “Report of the Commission to Assess the Threat to the United States from Electromagnetic Pulse (EMP) Attack: Critical National Infrastructures” to Congress in 2008 (Ref. 39), a HEMP attack over the Central U.S. could impact virtually the entire North American continent. The consequences of such an event are difficult to quantify with confidence. Experts affiliated with the aforementioned Commission and others familiar with the details of the Commission’s work have stated in Congressional testimony that such an event could “kill up to 90 percent of the national population through starvation, disease, and societal collapse.” 44,45 Most of these consequences are either direct or indirect impacts of the predicted collapse of virtually the entire U.S. Critical Infrastructure system in the wake of the attack.

Last, recent analyses by both the U.S. Department of Energy46 and the U.S. National Academies of Sciences, Engineering, and Medicine47 have concluded that cyber threats to the U.S. Grid from both state-level and substatelevel entities are likely to grow in number and sophistication in the coming years, posing a growing threat to the U.S. Grid.

These three “very bad day” scenarios are not creations of overzealous science fiction writers. A variety of mitigating actions to reduce both the vulnerability and the consequences of these events has been identified, and some are being implemented. However, the fact remains that events such as those described here have the potential to change life as we know it in the United States and other developed nations in the 21st century, whether the events occur individually, or simultaneously, and with or without coordinated physical attacks on Critical Infrastructure assets.

## 3

### CP

#### CP text: The member nations of the World Trade Organization should add more stringent requirements for filing secondary patents by requiring secondary patent filers to demonstrate increased efficacy as compared to the original. Solves all your offense by reducing purely strategic patents while permitting R and D for

Newsome 17, A [(JD candidate George Washington School of Law). (2017). Side effects of evergreening may include decreased competition & increased prices in the pharmaceutical industry. AIPLA Quarterly Journal, 45(4), 791-822] Justin

The current framework for evaluating a patent application, particularly the requirements of utility and nonobviousness, is insufficient for evaluating whether a secondary patent should be issued for a drug. Given that courts are tied to the low bar for utility and inconsistent with their application of nonobviousness,1 04 it is necessary to pass legislation creating a new utility requirement tailored to secondary pharmaceutical patents. This Note's Author proposes legislation language as follows: 35 U.S.C. § 106: Patentable Pharmaceutical Inventions

(a) Utility requirement for secondary patent: In the case of a pharmaceutical invention claiming an improvement on a patented invention, the applicant shall demonstrate through clear and convincing evidence in the written description that such invention has increased efficacy as compared to the original.

(b) Increased efficacy defined: As used in part (a), "increased efficacy" refers to a proven improvement in the mechanism of action, as disclosed in the patent claims. 0 5

(c) Mechanism of action defined: As used in part (b), "mechanism of action" refers to the process by which a drug functions to produce a therapeutic effect, as disclosed in the patent claims. 06

Under this legislation, the USPTO could grant a secondary patent only if the new formula's mechanism of action, or production of the intended pharmacological effect, in fact improves upon the patented drug's mechanism of action. For example, because VidaDrug is a chemotherapy drug, the new formula must include a change in the mechanism of action which causes an improvement in the efficacy of the drug's tumor-shrinking abilities to be eligible for a secondary patent. A formula tweak that reduces side effects is insufficient, because the underlying purpose of the drug - to treat cancer - remains unaffected.

Lowell provides some precedent for creating a higher utility standard. 07 This new standard would focus on a drug's overall improved efficacy, rather than a minor tweak in the formula that would mitigate or resolve a previously caused side effect. This standard would require holding the pharmaceutical industry to a higher standard than other industries, which could potentially conflict with the United States' TRIPS Agreement obligations with the WTO.

#### Solves best.

Newsome 17, A [(JD candidate George Washington School of Law). (2017). Side effects of evergreening may include decreased competition & increased prices in the pharmaceutical industry. AIPLA Quarterly Journal, 45(4), 791-822] Justin

Pharmaceutical patents are inherently different from software or manufacturing patents. 144 Pharmaceutical companies create life-saving drugs that carry a very serious benefit for a vulnerable group of consumers - patients. Because of this, the pharmaceutical industry should be held to a higher standard if its companies seek to prohibit affordable generic drugs from coming to the marketplace.

1. An Efficacy-Focused Standard Will Motivate Pharmaceutical Companies to Channel Resources to Creating Real Innovation Pharmaceutical companies argue that patent-life-cycle-management strategies (their preferred name for those tactics described herein as evergreening) are essential to ensuring they recoup R&D costs. 145 However, creation of a standard such as the one proposed here would ensure that pharmaceutical companies are properly incentivized to channel R&D resources to creating measurable change in the drugs, rather than creating minor changes that prolong the time they can profit off of monopolies at the expense of patients. For those industries in which R&D is more productive, like the pharmaceutical industry, "patent procedures should be refined to tighten the relationship between patents and the underlying inventions."14 6
2. A Higher Standard for Secondary Pharmaceutical Patents Will Increase Competition & Lead to Lower Prices The patent system enables pharmaceutical companies to retain market exclusivity for their drugs, allowing them to set high prices without an eye toward competition.1 47 The companies cite the need to recoup R&D costs as the driving factor for their pricing decisions,148 but critics say their main motivation is making a profit.'49 While the pharmaceutical companies' argument may hold weight, high prices for drugs have a negative impact on those patients who need those drugs, but cannot afford them.150 Tightening patent laws to prevent pharmaceutical companies from retaining patent protection for minor changes in their patented drugs will allow other companies to enter the marketplace sooner and drive prices down through competition. 5

## Case

### Solvency

#### 1] They don't solve their aff -- all they do is ensure companies only get one protection per invention – but theres no brightline for whats a new or old invention, so they cant stop evergreening. Companies will just slightly modify their invention and get a separate new patent and the aff has no litmus test for when an invention is significantlly new/different enough from past inventions

#### 2] Generic companies are just incompetent – even without patents, they wouldn’t be able to produce.

Fox 17, Erin. "How pharma companies game the system to keep drugs expensive." Harvard Business Review (April 6, 2017), https://hbr. org/2017/04/how-pharma-companies-game-the-system-to-keep-drugs-expensive (last visited on November 22, 2019) (2017). (director of Drug Information at University of Utah Health)//Elmer

Problems with generic drug makers Although makers of a branded drug are using a variety of tactics to create barriers to healthy competition, generic drug companies are often not helping their own case. In 2015, there were 267 recalls of generic drug products—more than one every other day. These recalls are for quality issues such as products not dissolving properly, becoming contaminated, or even being outright counterfeits. A few high-profile recalls have shaken the belief that generic drugs are truly the same. In 2014, the FDA withdrew approval of Budeprion XL 300 — Teva’s generic version of GlaxoSmithKline’s Wellbutrin XL. Testing showed the drug did not properly release its key ingredient, substantiating consumers’ claims that the generic was not equivalent. In addition, concerns about contaminated generic Lipitor caused the FDA to launch a $20 million initiative to test generic products to ensure they are truly therapeutically equivalent. In some cases, patent law also collides with the FDA’s manufacturing rules. For example, the Novartis patent for Diovan expired in 2012. Ranbaxy received exclusivity for 180 days for the first generic product. However, due to poor quality manufacturing, Ranbaxy couldn’t obtain final FDA approval for its generic version. The FDA banned shipments of Ranbaxy products to the United States. Ranbaxy ended up paying a $500 million fine, the largest penalty paid by a generic firm for violations. Due to these protracted problems with the company that had won exclusivity, a generic product did not become available until 2014. The two-year delay cost Medicare and Medicaid at least $900 million. Ranbaxy’s poor-quality manufacturing also delayed other key generic products like Valcyte and Nexium. Ironically, it was Mylan—involved in its own drug pricing scandal over its EpiPen allergy-reaction injector—that filed the first lawsuit to have the FDA strip Ranbaxy of its exclusivity. Mylan made multiple attempts to produce generic products but was overruled in the courts.

#### 3] Companies would just file a dozen patents upfront instead of secondary patents

**Holman 2020** (Christopher, Professor of Law, University of Missouri-Kansas City School of Law; J.D., University of California, Berkeley; Ph.D., University of California, Davis “Congress should decline ill-advised legislative proposals aimed at evergreening of pharmaceutical patent protection” *University of the Pacific Law Review*, 51(3), 493-524)DR 21

Under this interpretation of the bill, pharmaceutical companies would be motivated to dramatically change their patent filing practices. Instead of filing an application with claims that might be found to be directed towards two or more distinct inventions-and thus subject to a restriction requirement-the pharmaceutical company would need to file many patent applications simultaneously, each with claims directed towards the different inventions. For example, if this was the law at the time Amgen filed its initial patent application in 1983, it would have likely responded by filing at least seven applications with claims directed towards various methods, reagents, and products, rather than filing a single application that ultimately resulted in seven patents.

### Pandemics

#### 1] Pandemics promote peace AND solve war

Sebastian Mallaby 20 (Ford International Professor of Political Science at MIT and the director of MIT's Security Studies Program, 4-23-2020, "Do Pandemics Promote Peace?", Foreign Affairs, https://www.foreignaffairs.com/articles/china/2020-04-23/do-pandemics-promote-peace, accessed: 9-25-2020)//yeed

As the novel coronavirus infects the globe, states compete for scientific and medical supplies and blame one another for the pandemic’s spread. Policy analysts have started asking whether such tensions could eventually erupt into military conflict. Has the pandemic increased or decreased the motive and opportunity of states to wage war?

War is a risky business, with potentially very high costs. The historian Geoffrey Blainey argued in The Causes of War that most wars share a common characteristic at their outset: optimism. The belligerents usually start out sanguine about their odds of military success. When elites on both or all sides are confident, they are more willing to take the plunge—and less likely to negotiate, because they think they will come out better by fighting. Peace, by contrast, is served by pessimism. Even one party’s pessimism can be helpful: that party will be more inclined to negotiate and even accept an unfavorable bargain in order to avoid war.

When one side gains a sudden and pronounced advantage, however, this de-escalatory logic can break down: the optimistic side will increase its demands faster than the pessimistic side can appease. Some analysts worry that something like this could happen in U.S.-Chinese relations as a result of the new coronavirus. The United States is experiencing a moment of domestic crisis. China, some fear, might see the pandemic as playing to its advantage and be tempted to throw its military weight around in the western Pacific.

What these analysts miss is that COVID-19, the disease caused by the coronavirus, is weakening all of the great and middle powers more or less equally. None is likely to gain a meaningful advantage over the others. All will have ample reason to be pessimistic about their military capabilities and their overall readiness for war. For the duration of the pandemic, at least, and probably for years afterward, the odds of a war between major powers will go down, not up.

PAX EPIDEMICA?

A cursory survey of the scholarly literature on war and disease appears to confirm Blainey’s observation that pessimism is conducive to peace. Scholars have documented again and again how war creates permissive conditions for disease—in armies as well as civilians in the fought-over territories. But one seldom finds any discussion of epidemics causing wars or of wars deliberately started in the middle of widespread outbreaks of infectious disease. (The diseases that European colonists carried to the New World did weaken indigenous populations to the point that they were more vulnerable to conquest; in addition, some localized conflicts were fought during the influenza pandemic of 1919–21, but these were occasioned by major shifts in regional balances of power following the destruction of four empires in World War I.)

That sickness slows the march to war is partly due to the fact that war depends on people. When people fall ill, they can’t be counted on to perform well in combat. Military medicine made enormous strides in the years leading up to World War I, prior to which armies suffered higher numbers of casualties from disease than from combat. But pandemics still threaten military units, as those onboard U.S. and French aircraft carriers, hundreds of whom tested positive for COVID-19, know well. Sailors and soldiers in the field are among the most vulnerable because they are packed together. But even airmen are at risk, since they must take refuge from air attacks in bunkers, where the virus could also spread rapidly.

Ground campaigns in urban areas pose still greater dangers in pandemic times. Much recent ground combat has been in cities in poor countries with few or no public health resources, environments highly favorable to illness. Ground combat also usually produces prisoners, any of whom can be infected. A vaccine may eventually solve these problems, but an abundance of caution is likely to persist for some time after it comes into use.

Major outbreaks damage national economies, which are the source of military power.

The most important reason disease inhibits war is economic. Major outbreaks damage national economies, which are the source of military power. COVID-19 is a pandemic—by definition a worldwide phenomenon. All great and middle powers appear to be adversely affected, and all have reason to be pessimistic about their military prospects. Their economies are shrinking fast, and there is great uncertainty about when and how quickly they will start growing again.

#### 2] No disease extinction

Owen Cotton-Barratt 17, et al, PhD in Pure Mathematics, Oxford, Lecturer in Mathematics at Oxford, Research Associate at the Future of Humanity Institute, 2/3/2017, Existential Risk: Diplomacy and Governance, https://www.fhi.ox.ac.uk/wp-content/uploads/Existential-Risks-2017-01-23.pdf

For most of human history, natural pandemics have posed the greatest risk of mass global fatalities.37 However, there are some reasons to believe that natural pandemics are very unlikely to cause human extinction. Analysis of the International Union for Conservation of Nature (IUCN) red list database has shown that of the 833 recorded plant and animal species extinctions known to have occurred since 1500, less than 4% (31 species) were ascribed to infectious disease.38 None of the mammals and amphibians on this list were globally dispersed, and other factors aside from infectious disease also contributed to their extinction. It therefore seems that our own species, which is very numerous, globally dispersed, and capable of a rational response to problems, is very unlikely to be killed off by a natural pandemic.

One underlying explanation for this is that highly lethal pathogens can kill their hosts before they have a chance to spread, so there is a selective pressure for pathogens not to be highly lethal. Therefore, pathogens are likely to co-evolve with their hosts rather than kill all possible hosts.39

#### 3] their disease causes extinction ev( Millett 17) is citing disease impacts from 1918 doesn’t assume current tech

#### 4] no instability internal link --- if its tru that internal fraying and eocnom pbs, wouldn’t want to use up resources to lash out, coop

### Price

#### Markets ensure affordability; competition drives down drug prices over time

Boustany 18

Charles Boustany (physician and former congressman). “Americans Fund Most of the World’s Drug Research. Here’s How Trump Can End That.” Fortune. 9 August 2018. JDN. https://fortune.com/2018/08/09/trump-drugs-prices-pharmaceutical-research/

Just consider what happened with the numerous next-generation hepatitis C medicines released in recent years. These revolutionary drugs have been shown to cure 70-99% of patients. The first medicine gained FDA approval in late 2013 and debuted with a list price of $84,000 for a full course of treatment. Over the next four years, several competing drugs flooded the market.

Prices subsequently dropped about 70% a few years later, as manufacturers heavily discounted their cures to win market share. For some of these drugs, a full course of therapy is now less expensive than the average treatment costs incurred by patients using interferon and ribavirin—the go-to prescription regimen for decades. Patients on interferon and ribavirin frequently suffered severe side effects; the new next-generation cures are comparatively painless.

Or consider PCSK9 inhibitors. These drugs can sharply lower so-called bad cholesterol levels in patients at high risk of heart disease. A recent study found that one PCSK9 inhibitor, Praluent, reduced patients’ risk of cardiovascular disease by 15% and their risk of death by 29%. Despite the drug’s effectiveness, its manufacturer recently announced a 69% price cut to win market share.

In short, free-market competition works. It delivers cutting-edge medicines at reasonable prices.